Xintela AB (SE:XINT)
:XINT
Want to see SE:XINT full AI Analyst Report?
XINT Stock Chart & Stats
kr0.28
-kr0.02(-4.02%)
At close: 4:00 PM EST
kr0.28
-kr0.02(-4.02%)
Day’s Range― - ―
52-Week Rangekr0.17 - kr0.53
Previous CloseN/A
Volume22.80K
Average Volume (3M)554.92K
Market Cap
kr180.00M
Enterprise Valuekr137.16M
Total Cash (Recent Filing)kr23.21M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 28, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding861,266,850
10 Day Avg. Volume503,836
30 Day Avg. Volume554,918
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)kr11.94M
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtZero reported debt materially reduces interest burden and refinancing risk for a development-stage biotech. This structural flexibility supports continuing R&D and partnering talks without the immediate pressure of debt maturities, giving management more strategic optionality over the next several months.
Proprietary ITGA10 PlatformA patented integrin alpha-10 platform provides durable IP and program optionality across regenerative medicine and oncology. Platform-based franchises enable multiple indication shots on goal, support out-licensing/co-development economics, and create long-term partnership and royalty potential.
Positive Gross Profit In Recent YearsReported positive gross profit in 2024–2025 indicates the company’s direct cost structure can be covered by program revenues or contract work. If revenue scale increases, this suggests potential for scalable gross margins and a clearer path to improving operating leverage over a medium-term horizon.
Bears Say
Sustained Cash BurnPersistent large negative operating cash flow demonstrates ongoing financing dependency. Over a multi-quarter horizon this raises dilution and financing risk, constrains the ability to advance multiple programs concurrently, and forces priority decisions that can slow development timelines.
Negative Shareholders' EquityA negative equity position materially weakens balance-sheet resilience, limiting borrowing capacity and raising the likelihood of equity raises or restructuring. This structural weakness reduces optionality for long-term investment and increases downside risk to existing shareholders.
Volatile And Declining Revenue BaseA small, volatile revenue base with recent negative growth undermines the company’s path to sustainable profitability. When revenues decline versus a sizable fixed cost base, milestone-driven financing becomes less predictable and partnership or licensing leverage is harder to achieve reliably.
Xintela AB News
XINT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was kr0.17 and its highest was kr0.53 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is kr180.00M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is Aug 28, 2026 which is in 76 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on May 29, 2026. The company reported -kr0.01 earnings per share for the quarter, the consensus estimate of -kr0.01 by kr0.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is -0.01.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of -kr0.01 in its last earnings report, expectations of -kr0.01. Following the earnings report the stock price went down -5.394%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in SE:XINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.
Technical Analysis
Isofol Medical AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―